Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective

about

Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective

Item

http://www.wikidata.org/entity/Q57177486

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в липні 2018

@uk

name

Personalized medicine in non-s ...... a pharmacogenomics perspective

@en

Personalized medicine in non-s ...... a pharmacogenomics perspective

@nl

type

Item

label

Personalized medicine in non-s ...... a pharmacogenomics perspective

@en

Personalized medicine in non-s ...... a pharmacogenomics perspective

@nl

prefLabel

Personalized medicine in non-s ...... a pharmacogenomics perspective

@en

Personalized medicine in non-s ...... a pharmacogenomics perspective

@nl

P1476

Personalized medicine in non-s ...... a pharmacogenomics perspective

@en

P2093

Guiqing Cai

http://www.w3.org/2001/XMLSchema#string

Peter C Hu

http://www.w3.org/2001/XMLSchema#string

Wenxiao Jiang

http://www.w3.org/2001/XMLSchema#string

Yue Wang

http://www.w3.org/2001/XMLSchema#string

P2860

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

Molecular pathology of lung cancer: key to personalized medicine.

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

P304

530-538

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.APSB.2018.04.005

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30109178

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

P932

6089847

http://www.w3.org/2001/XMLSchema#string